Efficacy of Fluvoxamine in Obsessive-Compulsive Disorder: A Double-blind Comparison With Placebo

Wayne K. Goodman, Lawrence H. Price, Pedro L. Delgado, George R. Heninger, Dennis S. Charney

Research output: Contribution to journalArticlepeer-review

357 Scopus citations


A six- to eight-week double-blind placebo-controlled trial of the potent and selective serotonin reuptake inhibitor fluvoxamine was conducted in 42 patients with primary obsessive-compulsive disorder (OCD). Approximately one half of the patients also had symptoms of major depression. Fluvoxamine was significantly better than placebo on all measures of obsessive-compulsive symptoms. Nine of 21 patients were responders ("much improved") with fluvoxamine compared with no responders with placebo, and fluvoxamine was effective in patients with OCD both with and without secondary depression. Response of OCD was not correlated with severity of baseline depression. These data lend partial support to the serotonin hypothesis of OCD. However, since a number of patients failed to respond to fluvoxamine, the role of other neurochemical systems in this disorder needs to be explored.

Original languageEnglish (US)
Pages (from-to)36-44
Number of pages9
JournalArchives of General Psychiatry
Issue number1
StatePublished - Jan 1989

ASJC Scopus subject areas

  • Arts and Humanities (miscellaneous)
  • Psychiatry and Mental health


Dive into the research topics of 'Efficacy of Fluvoxamine in Obsessive-Compulsive Disorder: A Double-blind Comparison With Placebo'. Together they form a unique fingerprint.

Cite this